trending Market Intelligence /marketintelligence/en/news-insights/trending/esn94jocyhu9ymdlfcqm1g2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

AbbVie stocks drop on results from lung cancer drug


Needham & Company is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection


Banking Essentials Newsletter - February Edition


Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021

AbbVie stocks drop on results from lung cancer drug

AbbVie Inc. said it will not seek accelerated approval for its cancer drug Rova-T in the U.S. as a third-line treatment for small cell lung cancer.

The company's stock was down 10.98% to $100.10 per share as of 10:28 a.m. ET on March 22.

The decision is based on the results of a phase 2 trial, known as Trinity, in the affected patient population. The North Chicago, Ill.-based biotech company was investigating the treatment's effectiveness in subjects whose cancer was unresponsive to two prior therapies.

In the study, only 29% of patients saw a reduction in their cancer. Patients on the medicine survived, on average, 5.6 months, and the probability of patients alive at 12 months was 17.5%.

The company also observed a "magnitude of effect across multiple parameters in this single-arm study." These effects included fatigue, affecting 38% of patients, and photosensitivity reaction, affecting 36% of study participants.

Although the results of the study are not what the company had desired, it will continue to study the treatment in first-line and second-line settings.

The company is investigating the drug, which is also known as rovalpituzumab tesirine, in those settings in the Meru and Tahoe trials. The phase 3, or late-stage, clinical trials have enrolled patients who either did not receive prior therapy or who did not get better after being treated once.